Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
42C.SI
SelliX Biopharma Ltd. · Healthcare · Singapore · $361M · Avg Vol: $6M/d
28
StockRankGet insider-trade alerts
Q
25
V
20
M
69
P/E (TTM)
—
ROE
-101.4%
D/E
0.4x
Dividend %
—
COMPANY DESCRIPTION
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, Australia and internationally.
FINANCIAL SUMMARY (SGD)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | — | 5.9M | 6.0M | 7.8M | 6.9M | 5.0% | 6.9M |
| EPS (SGD) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | — | -0.01 |
| Shares | — | 775.0M | 777.1M | 888.0M | 1.1B | +37.8% | 1.1B |
| Debt | — | 4.3M | 5.2M | 5.9M | 5.8M | 10.2% | 5.8M |
| Equity | — | 15.9M | 4.3M | 0.4M | 15.4M | -1.0% | — |
| Op CF | — | -7.7M | -6.6M | -3.8M | -7.5M | — | -7.5M |
| Inv CF | — | -0.7M | 1.1M | -0.2M | -0.1M | — | — |
| Fin CF | — | 1.4M | 0.7M | 3.1M | 21.5M | — | — |
Loading 1Y...
PRICE (1Y)+9.2%
SMA 50SMA 200
Close
$0.3256
RSI (14)
17.5
52W High
$0.459
From 52W High
0.7%
SCORE BREAKDOWN
Quality
25
ROIC
-426.0%1.0
ROE
-101.4%10.0
GP/Assets
21.6%49.9
Op. Margin
-221.3%14.2
FCF/Assets
-35.1%11.3
Piotroski
550.3
Int. Cover
-30.6x15.9
D/E Ratio
0.38x36.5
Current Ratio
1.86x35.6
Value
20
P/E (TTM)
—N/A
EV/EBITDA
-48.1x25.0
P/FCF
—N/A
P/B
27.7x4.1
P/S
66.2x9.1
Div Yield
—N/A
Momentum
69
52W High %
71%50.4
RS 6M
94%96.5
SMA 50/200
1.52x98.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$361M
P/E (Forward)
-41.5x
Gross Margin
35.5%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 42C.SI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 42C.SI | iX Biopharma Ltd.(you) | $361M | 28 | Sell |
| 2629.HK | Mirxes Holding Company Limited | $472M | 18 | Strong Sell |
| A50.SI | Thomson Medical Group Limited | $1.1B | 29 | Sell |
| QC7.SI | Q & M Dental Group (Singapore) Limited | $410M | 52 | Hold |
| 950210.KS | Prestige BioPharma Limited | $269M | 7 | Strong Sell |
| 1D4.SI | Aoxin Q & M Dental Group Limited | $196M | 42 | Hold |
| FHH.SI | Foundation Healthcare Holdings Limited | $747M | 56 | Hold |
| BMGL | Basel Medical Group Ltd | $122M | 3 | Strong Sell |
| 8YY.SI | Embracing Future Holdings Limited | $54M | 3 | Strong Sell |
| BSL.SI | Raffles Medical Group Ltd | $1.3B | 72 | Buy |
Peer medians: ROE 5.2% · P/E 18.4x · Gross margin 43.9%